Number of the records: 1
In vitro study of 2,3-dehydrosilybin and its galloyl esters as potential inhibitors of angiogenesis
- 1.
SYSNO ASEP 0465585 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title In vitro study of 2,3-dehydrosilybin and its galloyl esters as potential inhibitors of angiogenesis Author(s) Pivodová, V. (CZ)
Zahler, S. (DE)
Karas, D. (CZ)
Valentová, Kateřina (MBU-M) RID, ORCID
Ulrichová, J. (CZ)Source Title Pharmazie. - : Avoxa - ISSN 0031-7144
Roč. 71, č. 8 (2016), s. 478-483Number of pages 6 s. Language eng - English Country DE - Germany Keywords NF-KAPPA-B ; VASCULAR ENDOTHELIAL-CELLS ; GROWTH-FACTOR Subject RIV EE - Microbiology, Virology R&D Projects GA15-03037S GA ČR - Czech Science Foundation (CSF) Institutional support MBU-M - RVO:61388971 UT WOS 000385261200009 EID SCOPUS 84989864018 Annotation 2,3-Dehydrosilybin exhibits substantial anticancer and antiangiogenic effects, which can be potentially improved by semi-synthetic modification such as esterification with gallic acid. The aim of this study was to examine the potential antiangiogenic effect of 2,3-dehydrosilybin and its galloyl esters (3-O-galloyl-2,3-dehydrosilybin; 7-O-galloyl-2,3-dehydrosilybin; 20-O-galloyl-2,3-dehydrosilybin and 23-O-galloyl-2,3-dehydrosilybin) and to determine which molecular mechanism could be responsible for their activity. The effect on cell proliferation, tube formation, signal transduction pathways (PI3K/Akt and ERK) and the cell cycle was studied in human microvascular endothelial cells (HMEC). The results showed that all compounds decreased the growth of HMEC, but the strongest effect was observed for 20-O-galloyl-2,3-dehydrosilybin at 5 mu mol/l. In addition, at 5 and 10 mu mol/l, this was the only compound that significantly inhibited HMEC tube formation. Based on an assessment of Akt and ERK1/2 expression, we suggest that 20-O-galloyl-2,3-dehydrosilybin influences the angiogenic process through the Akt pathway. Workplace Institute of Microbiology Contact Eliška Spurná, eliska.spurna@biomed.cas.cz, Tel.: 241 062 231 Year of Publishing 2017
Number of the records: 1